EyePoint Posts $95.6M Quarterly Loss, Pins Future on DME With Cash Into Late 2027
EYPT is trading near its 52-week low of $0.331 (8.9% above the low).
Summary
EyePoint burned $95.6 million in Q3 2026, or $1.07 a share, versus a $59.7 million loss a year earlier, as R&D spending on the DURAVYU Phase 3 program pushed operating expenses to $97.6 million from $63.0 million. Cash and marketable securities fell to $118 million at September 30 from $306 million at year-end 2025. Management says that balance, plus $10 million raised after quarter-end under its at-the-market facility and the cost cuts, funds operations only into late Q3 2027 — and the DME topline from COMO and CAPRI is not expected until early Q4 2027, so the company is likely to need more money before that readout. The plan now rests entirely on DME: both Phase 3 trials are fully enrolled with over 550 patients, backed by the Phase 2 VERONA result of a +7.1-letter BCVA gain and 73% supplement-free at Week 24. The ~53% workforce reduction and wind-down of wet AMD are expected to save about $30 million a year, and the company says it will keep pursuing business development and financing to stretch the runway.
At the time of this announcement, EYPT was trading at $0.36 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $30.7M. The 52-week trading range was $0.33 to $19.11. This news item was assessed with negative market sentiment and an importance score of 7 out of 10. Source: GlobeNewswire.